1. Predictors of antiplatelet cessation in a real-world patient population undergoing non-cardiac surgery after PCI
- Author
-
Anoop N, Koshy, Davide, Cao, Matthew A, Levin, Samantha, Sartori, Gennaro, Giustino, Htoo, Kyaw, Bimmer, Claessen, Zhongjie, Zhang, Johny, Nicolas, Anton, Camaj, Anastasios, Roumeliotis, Rishi, Chandiramani, Rashi, Bedekar, Zaha, Waseem, Shiv, Bagga, Annapoorna, Kini, Samin K, Sharma, and Roxana, Mehran
- Subjects
Percutaneous Coronary Intervention ,Treatment Outcome ,Aspirin ,Humans ,Drug-Eluting Stents ,Cardiology and Cardiovascular Medicine ,Prasugrel Hydrochloride ,Platelet Aggregation Inhibitors - Abstract
The optimal perioperative management of antiplatelet therapy (APT) therapy in patients undergoing noncardiac surgery (NCS) following percutaneous coronary intervention (PCI) is unclear. We sought to identify predictors of APT cessation in a real-world cohort of patients undergoing NCS within 1 year of PCI.Consecutive patients undergoing PCI at a tertiary center between 2011 and 2018 were prospectively enrolled. Perioperative interruption of APT was defined as cessation of either aspirin or P2YA total of 1092 surgeries corresponding to 747 patients were identified. Overall, there were 487 (44.6%) preoperative antiplatelet interruptions: discontinuation of either P2YIn this contemporary cohort of post-PCI patients undergoing NCS, patient-, angiographic- and surgery-specific factors all affected decision-making regarding APT cessation. Our findings reflective of real-world practice, highlight the importance of a multidisciplinary team approach to individualize decision making in these patients.
- Published
- 2022